Found: 22
Select item for more details and to access through your institution.
Inflammatory profile of lower risk myelodysplastic syndromes.
- Published in:
- British Journal of Haematology, 2024, v. 205, n. 3, p. 1044, doi. 10.1111/bjh.19530
- By:
- Publication type:
- Article
Cause of death and excess mortality in patients with lower‐risk myelodysplastic syndromes (MDS): A report from the European MDS registry.
- Published in:
- British Journal of Haematology, 2023, v. 200, n. 4, p. 451, doi. 10.1111/bjh.18542
- By:
- Publication type:
- Article
Successful treatment of a PNH patient non‐responsive to eculizumab with the novel complement C5 inhibitor coversin (nomacopan).
- Published in:
- British Journal of Haematology, 2020, v. 188, n. 2, p. 334, doi. 10.1111/bjh.16305
- By:
- Publication type:
- Article
Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes.
- Published in:
- Nature Genetics, 2010, v. 42, n. 8, p. 665, doi. 10.1038/ng.620
- By:
- Publication type:
- Article
Acquired mutations in TET2 are common in myelodysplastic syndromes.
- Published in:
- Nature Genetics, 2009, v. 41, n. 7, p. 838, doi. 10.1038/ng.391
- By:
- Publication type:
- Article
Comparative clinical efficacy and safety of biosimilar ABP 959 and eculizumab reference product in patients with paroxysmal nocturnal hemoglobinuria.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 11, p. 2108, doi. 10.1002/ajh.27456
- By:
- Publication type:
- Article
Development of a target concentration intervention to individualize paroxysmal nocturnal hemoglobinuria treatment with pegcetacoplan.
- Published in:
- Annals of Hematology, 2024, v. 103, n. 7, p. 2267, doi. 10.1007/s00277-024-05699-8
- By:
- Publication type:
- Article
Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial.
- Published in:
- Annals of Hematology, 2014, v. 93, n. 8, p. 1401, doi. 10.1007/s00277-014-2055-7
- By:
- Publication type:
- Article
Dose optimalization of subcutaneous ravulizumab is predicted to yield significant savings and to improve patient friendliness.
- Published in:
- British Journal of Clinical Pharmacology, 2023, v. 89, n. 3, p. 1211, doi. 10.1111/bcp.15602
- By:
- Publication type:
- Article
The potential of individualized dosing of ravulizumab to improve patient‐friendliness of paroxysmal nocturnal haemoglobinuria treatment at reduced costs.
- Published in:
- British Journal of Clinical Pharmacology, 2021, v. 87, n. 8, p. 3359, doi. 10.1111/bcp.14748
- By:
- Publication type:
- Article
Placental disposition of eculizumab, C5 and C5‐eculizumab in two pregnancies of a woman with paroxysmal nocturnal haemoglobinuria.
- Published in:
- British Journal of Clinical Pharmacology, 2021, v. 87, n. 4, p. 2128, doi. 10.1111/bcp.14565
- By:
- Publication type:
- Article
Nationwide study of eculizumab in paroxysmal nocturnal hemoglobinuria: Evaluation of treatment indications and outcomes.
- Published in:
- European Journal of Haematology, 2023, v. 110, n. 6, p. 648, doi. 10.1111/ejh.13946
- By:
- Publication type:
- Article
Long‐term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2‐year results from two pivotal phase 3 studies.
- Published in:
- European Journal of Haematology, 2022, v. 109, n. 3, p. 205, doi. 10.1111/ejh.13783
- By:
- Publication type:
- Article
One‐year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab.
- Published in:
- European Journal of Haematology, 2021, v. 106, n. 3, p. 389, doi. 10.1111/ejh.13564
- By:
- Publication type:
- Article
Raising the standards of patient‐centered outcomes research in myelodysplastic syndromes: Clinical utility and validation of the subscales of the QUALMS from the MDS‐RIGHT project.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 6, p. 7529, doi. 10.1002/cam4.5487
- By:
- Publication type:
- Article
Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria.
- Published in:
- PLoS ONE, 2020, v. 15, n. 9, p. 1, doi. 10.1371/journal.pone.0237497
- By:
- Publication type:
- Article
Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial.
- Published in:
- 2008
- By:
- Publication type:
- journal article
Erythroid Predominance in Bone Marrow Biopsies of Acute Myeloid Leukemia Patients after Decitabine Treatment Correlates with Mutation Profile and Complete Remission.
- Published in:
- Pathobiology, 2024, v. 91, n. 5, p. 326, doi. 10.1159/000538953
- By:
- Publication type:
- Article
Apoptosis-Related Gene Expression Profiling in Hematopoietic Cell Fractions of MDS Patients.
- Published in:
- PLoS ONE, 2016, v. 11, n. 11, p. 1, doi. 10.1371/journal.pone.0165582
- By:
- Publication type:
- Article
1041. Delayed Infusion of Hematopoietic Stem Cells Improves Engraftment after Low-Dose Parenterally Administered Busulfan in a Congenic Murine Transplant Model
- Published in:
- 2005
- By:
- Publication type:
- Abstract
Anti Thymocyte Globulin-Based Treatment for Acquired Bone Marrow Failure in Adults.
- Published in:
- Cells (2073-4409), 2021, v. 10, n. 11, p. 2905, doi. 10.3390/cells10112905
- By:
- Publication type:
- Article
Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab.
- Published in:
- 2019
- By:
- Publication type:
- journal article